Evidence map›Paper›PMID 39840253›Full record

ReviewInternational journal of cardiology. Heart & vasculature2025

Transcatheter versus surgical aortic valve replacement in patients with aortic stenosis with a small aortic annulus: A meta-analysis with reconstructed time to event data.

Ahmed K Awad, Zina Otmani, Mazen Negmeldin Aly Yassin, Ahmed Mazen Amin, Farouq Bahaa Alahmed, Zineddine Belabaci, Haya A Hegazy, Unaiza Ahmad, Mohamed Abuelazm

Abstract readReview
In one paragraph

Review in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2025
    Article
  2. Transcatheter aortic valve implantation: latest evidence, gaps in knowledge, and future directions.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025
    Review
  3. TAVI vs SAVR: The timeless showdown in aortic valve replacement.International journal of cardiology. Heart & vasculature · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ahmed K AwadFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Zina OtmaniFaculty of Medicine, Mouloud Mammeri University, Tizi Ouzou, Algeria.
Mazen Negmeldin Aly YassinFaculty of Medicine, Cairo University, Cairo, Egypt.
Ahmed Mazen AminFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Farouq Bahaa AlahmedFaculty of Medicine, Alexandria University, Egypt.
Zineddine BelabaciFaculty of Medicine, Djillali Liabes University, Sidi Bel Abbes, Algeria.
Haya A HegazyFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Unaiza AhmadPunjab Medical College, Faisalabad, Pakistan.
Mohamed AbuelazmFaculty of Medicine, Tanta University, Tanta, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Aortic stenosis (AS) remains a prevalent and serious global health concern, exacerbated by an aging population worldwide. This valvular disease, when symptomatic and without appropriate intervention, severe AS can drastically reduce life expectancy. In our systematic review and Methods: We searched PubMed, EMBASE, Cochrane, Web of Science, and Scopus from inception till May 2024. The risk ratio (RR) and mean difference (MD) with a 95 % confidence interval (CI) are provided as effect size estimates, with all analyses being conducted using RevMan 5.4. Results: Eleven studies with 3,670 patients were included. TAVR significantly increased the risk of 2-year new permanent pacemaker implantation (PPI) (RR = 2.42; 95 % CI: [1.70-3.44], P < 0.0001) and major vascular complications (RR = 3.73; 95 % CI: [1.98-6.99], P < 0.0001) than SAVR. However, TAVR significantly decreased the risk of patient-prosthesis mismatch (PPM) (RR = 0.56; 95 % CI: [0.48-0.65], P < 0.00001) and new-onset atrial fibrillation (AF) (RR = 0.31; 95 % CI: [0.23-0.41], P < 0.00001). Also, SAVR reduced the risk of paravalvular leak (PVL) (RR = 3.35; 95 % CI: [1.79-6.27], P = 0.0002). Conclusion: TAVR had a significantly reduced risk of PPM and new-onset AF but with increased PPI and vascular complications. Also, TAVR significantly improved EOA and iEOA. Furthermore, SAVR had less risk of PVL, and better LVEF improvement at predischarge. Therefore, TAVR and SAVR remain valid alternatives, and decisions should be based on anatomy of the annulus and aortic root,operative risk, and comorbidities.

Indexed as

Cardiac surgeryCardiologyClinical trialInterventionReviewValve

Identifiers

PMID39840253
PMCPMC11745981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.